![N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders](/docs/US/2019-02-26/US10214533B2/abs.jpg.600x600.jpg)
- Patent Title: N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
-
Application No.: US15956311Application Date: 2018-04-18
-
Publication No.: US10214533B2Publication Date: 2019-02-26
- Inventor: Hamid Hoveyda , Guillaume Dutheuil , Graeme Fraser
- Applicant: OGEDA SA
- Applicant Address: BE Charleroi
- Assignee: OGEDA SA
- Current Assignee: OGEDA SA
- Current Assignee Address: BE Charleroi
- Agency: Young & Thompson
- Priority: EP13161864 20130329
- Main IPC: C07D487/04
- IPC: C07D487/04 ; A61K31/4985
![N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders](/abs-image/US/2019/02/26/US10214533B2/abs.jpg.150x150.jpg)
Abstract:
Novel compounds of Formula I and their use in therapeutic treatments.
Public/Granted literature
Information query
